pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
SARCLISA 20mg/mL concentrate for solution for infusion.
Phase 2 · small molecule · Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation
SARCLISA 20mg/mL concentrate for solution for infusion. for Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP200067
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation
- Status
- active
- Trials
- 1